{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:41:33Z","timestamp":1760812893431,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.trim.2022.101705","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T12:26:25Z","timestamp":1661862385000},"page":"101705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Previous therapy with immune checkpoint inhibitor as a cause of hypothyroidism, myositis, and renal insufficiency in a candidate for allogeneic hematopoietic transplantation"],"prefix":"10.1016","volume":"75","author":[{"given":"Andrea","family":"Duminuco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Cupri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio A.","family":"Milone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelita","family":"Marcantoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Leotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Chiarenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Milone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2022.101705_bb0005","article-title":"Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology","volume":"24","author":"Lee","year":"2019","journal-title":"Molecules [Internet]."},{"key":"10.1016\/j.trim.2022.101705_bb0010","series-title":"KEYNOTE-204: Randomized, Open-Label, Phase III Study of Pembrolizumab (pembro) Versus Brentuximab Vedotin (BV) in Relapsed or Refractory Classic Hodgkin Lymphoma (R\/R cHL)","volume":"38","author":"Kuruvilla","year":"2020"},{"issue":"14","key":"10.1016\/j.trim.2022.101705_bb0015","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol. [Internet]."},{"issue":"4","key":"10.1016\/j.trim.2022.101705_bb0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1470-2045(21)00138-8","article-title":"Relapsed or refractory classical Hodgkin lymphoma: which immunotherapy, and when?","volume":"22","author":"Vassilakopoulos","year":"2021","journal-title":"Lancet Oncol. [Internet]"},{"issue":"7","key":"10.1016\/j.trim.2022.101705_bb0025","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"2","key":"10.1016\/j.trim.2022.101705_bb0030","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J. Am. Soc. Nephrol. [Internet]."},{"key":"10.1016\/j.trim.2022.101705_bb0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur. J. Cancer [Internet]."},{"issue":"3","key":"10.1016\/j.trim.2022.101705_bb0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"De Filette","year":"2019","journal-title":"Horm. Metab. Res. [Internet]."},{"issue":"1","key":"10.1016\/j.trim.2022.101705_bb0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev. [Internet]"},{"issue":"8","key":"10.1016\/j.trim.2022.101705_bb0050","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J. Clin. Endocrinol. Metab. [Internet]"},{"issue":"4","key":"10.1016\/j.trim.2022.101705_bb0055","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11154-016-9357-0","article-title":"Hypothyroid myopathy: A peculiar clinical presentation of thyroid failure. Review of the literature","volume":"17","author":"Sindoni","year":"2016","journal-title":"Rev. Endocr. Metab. Disord. [Internet]."},{"issue":"3","key":"10.1016\/j.trim.2022.101705_bb0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/07435800500371706","article-title":"Serum creatine kinase levels in overt and subclinical hypothyroidism","volume":"31","author":"Hekimsoy","year":"2005","journal-title":"Endocr. Res. [Internet]"},{"issue":"6","key":"10.1016\/j.trim.2022.101705_bb0065","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/ndt\/9.6.637","article-title":"Relationship between elevated creatine phosphokinase and the clinical spectrum of rhabdomyolysis","volume":"9","author":"Veenstra","year":"1994","journal-title":"Nephrol. Dial. Transplant. [Internet]."},{"key":"10.1016\/j.trim.2022.101705_bb0070","series-title":"Myopathy as the Persistently Isolated Symptomatology of Primary Autoimmune Hypothyroidism","first-page":"1033","volume":"8(11)","author":"Rodolico","year":"2009"},{"key":"10.1016\/j.trim.2022.101705_bb0075","doi-asserted-by":"crossref","first-page":"101045","DOI":"10.1016\/j.mam.2021.101045","article-title":"The peroxidatic activities of myoglobin and hemoglobin, their pathological consequences and possible medical interventions","volume":"84","author":"Wilson","year":"2022","journal-title":"Mol. Asp. Med."},{"issue":"18","key":"10.1016\/j.trim.2022.101705_bb0080","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood-2014-11-608406","article-title":"Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation","volume":"125","author":"Roberto","year":"2015","journal-title":"Blood [Internet]."},{"issue":"17","key":"10.1016\/j.trim.2022.101705_bb0085","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/bloodadvances.2018019208","article-title":"Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide","volume":"2","author":"Schoch","year":"2018","journal-title":"Blood Adv. [Internet]."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422001794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422001794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:01:20Z","timestamp":1760810480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327422001794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":17,"alternative-id":["S0966327422001794"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2022.101705","relation":{},"ISSN":["0966-3274"],"issn-type":[{"type":"print","value":"0966-3274"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Previous therapy with immune checkpoint inhibitor as a cause of hypothyroidism, myositis, and renal insufficiency in a candidate for allogeneic hematopoietic transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2022.101705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101705"}}